Protective Effect of Rolipram in Experimental Autoimmune Neuritis: Protection is Associated with Down-Regulation of IFN-γ and Inflammatory Chemokines as Well as Up-Regulation of IL-4 in Peripheral Nervous System

References

• Hughes R. A., Atkinson P., Coates P., Hall S., Leibow-Itz S. Sural nerve biopsies in Guillain-Barre syndrome: Axonal degeneration and macrophage-associated demyelina-tion and absence of cytomegalovirus genome. Muscle & Nerve 1992; 15: 568–75
   PubMed Web of Science ®Google Scholar
• Dahle C., Ekerfelt C., Vrethem M., Samuelsson M., Ernerudh J. T helper 2 like cytokine responses to peptides from PO and P2 myelin proteins during the recovery phase of the Guillain-Barre syndrome. J. Neurol. Sci. 1997; 153: 54–60
   PubMed Web of Science ®Google Scholar
• Thornton C. A, Griggs C. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann. Neurol 1994; 35: 749–4752
   PubMed Web of Science ®Google Scholar
• Yoshikawa M., Suzumura A., Tamaru T., Takayanagi T., Savvada M. Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mult. Scler 1999; 5: 126–133
   PubMed Web of Science ®Google Scholar
• Zou L. P., Deretzi G., Pelidou S. H., Levi M., Wahren B., Quiding C., ZhuRolipram J. suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats. Neuropharmacology 2000; 39: 324–333
   PubMed Web of Science ®Google Scholar
• Sommer N., Loschmann P. A., Northoff G. H., Weller M., Steinbrecher A., Steinbach J. P., Lichtenfels R., Meyer-Mann R., Riethmuller A., Fontana A., Dichgans J., Martin R. The antidepressant rolipram suppresses, cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1995; 1: 244–8
   PubMed Web of Science ®Google Scholar
• Sommer N., Martin R., McFarland H. F., Quigley L., Can-Nella B., Raine C. S., Scott D. E., Raine C. S., Scott D. E., Loschmann P. A, Racke M. K. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuwimmunol 1997; 79: 54–61
   PubMed Web of Science ®Google Scholar
• Rott O., Cash E., Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1 -but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol 1993; 23: 1754–1751
   Web of Science ®Google Scholar
• Constantinescu C. S., Hilliard B., Lavi E., Ventura E., Venkatesh V., Rostami A. Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline. Neurol. Sci. 1996; 143: 14–18
   Web of Science ®Google Scholar
• Olee T., Powers J. M, Brostoff S. W. A. T cell epitope for experimental allergic neuritis. J. Neuroimmunol 1988; 19: 167–73
   PubMed Web of Science ®Google Scholar
• Norton W. T, Poduslo S. E. Myelination in rat brain: Method of myelin isolation. J. Neurochem 1973; 21: 749–57
   PubMed Web of Science ®Google Scholar
• Martinez I., Puerta C., Redondo C., Garcia-Merino A. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokine, adhension molecules and the inducible nitric oxide synthase. J. Neurol. Sci. 1999; 164: 13–23
   PubMed Web of Science ®Google Scholar
• Folcik V. A., Smith T., O'Bryant S., Kawczak J. A., Zhu B., Sakurai H., Kajiwara A., Staddon J. M., Glabinski A., Chernosky A. L., Tani M., Johnson J. M., Tuohy V. K., Rubin L. L, Ransohoff R. M. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J. Neuroimmunol 1999; 97: 119–128
   PubMed Web of Science ®Google Scholar
• Pette M., Muraro P. A., Pette D. F., Dinter H., McFarland H. F, Martin R. Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-spe-cific T cell clones. J Neuroimmunol 1999; 98: 147–156
   PubMed Web of Science ®Google Scholar
• Hartung H. P., Pollard J. D., Harvey G., Toyka K. V. Immunopathogenesis and treatment of the Guillain-Barre syndrome. Part I. Muscle & Nerve 1995; 18: 137–153
   PubMed Web of Science ®Google Scholar
• Zhu J., Bai X. F., Mix E., Hqjeberg B., Link H. Cytokines dichotomy in the peripheral nervous tissues influence the outcome of experimental allergic neuritis: Dynamics of mRNA expression for IL-β, IL-6, 11-10, IL-12, TNF-α and TNF-β as well as cytolysin. Clin. Immunol. Immun-opathol 1997; 84: 85–94
   PubMedGoogle Scholar
• Luster A. D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 1998; 338: 436–445
   PubMed Web of Science ®Google Scholar
• Ransohoff R. M., Glabinski A., Tani M. Chemokines in immune-mediated inflammation of the central nervous system. Cytokine. Growth. Factor. Reviews 1996; 7: 35–46
   PubMedGoogle Scholar
• Zou L. P., Pelidou S. H., Abbas N., Deretzi G., Mix E., Schaltzbeerg M., Winblad B., Zhu J. Dynamics of production of MlP-1α, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats. J. Neuroimmunol 1999; 98: 168–175
   PubMed Web of Science ®Google Scholar
• Zhu J., Mix E., Link H. Cytokine production and the pathogenesis of experimental allergic neuritis and Guillain-Barré syndrome. J. Neurommunol 1998; 84: 40–52
   PubMed Web of Science ®Google Scholar
• Jung S., Zielasek J., Kollner G., Donhauser T., Toyka K., Hartung H. P. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol 1996; 68: 1–11
   PubMed Web of Science ®Google Scholar
• Zhu J., Mix E., Olsson T., Link H. Cellular mRNA expression of interferon-y, interleukin 4 and transforming growth factor (5 by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis. Clin. Exp. Immunol 1994; 98: 306–312
   PubMed Web of Science ®Google Scholar
• Zou L. P., Zhu J., Deng G. M., Levi M., Wahren B., Diab A., Hiller J., Link H. Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rats experimental autoimmune neuritis. J. Neuwimmunol 1998; 85: 137–145
   PubMed Web of Science ®Google Scholar
• Deretzi G., Zou L. P., Pelidou H. S., Nennesmo L., Levi M., Wahren B., Mix E., Zhu J. Nasal administration of recombinant rat IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelination. J. Autoimmunity 1999; 12: 81–89
   PubMed Web of Science ®Google Scholar
• Lacour M., Arrighi J. F., Muller K. M., Carlberg C., Saurat J. H., Hauser C. cAMP upregulates IL-4 and IL-5 production from activated CD4+ T cells while decreasing IL-2 release and NF-AT induction. Int Immunol 1994; 6: 1333–1343
   PubMed Web of Science ®Google Scholar
• Novak T. J., Rothenberg E. V. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc Natl AcadSciUSA 1990; 87: 9353–9357
   PubMed Web of Science ®Google Scholar